Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Alemtuzumab-based therapy for Secondary Malignant Histiocytosis arising from Pre-B-ALL. Leuk Res Rep 2018;9:5-8

Date

12/22/2017

Pubmed ID

29264111

Pubmed Central ID

PMC5726878

DOI

10.1016/j.lrr.2017.11.003

Scopus ID

2-s2.0-85037688019   2 Citations

Abstract

•Secondary Malignant Histiocytosis (SMH) is an exceedingly rare, life-threatening condition that invariably occurs in the presence of an underlying monoclonal hematologic disorder. Prognosis of SMH remains dismal and there is no established treatment. •We report a case of a patient who developed SMH during induction chemotherapy for his underlying pre-B-ALL, that caused persistently high fevers and was only diagnosed by a marrow while cytopenic in phase 2 induction. He was treated with alemtuzumab-based therapy that reduced the histiocytic infiltration of the bone marrow from 80% to 15% and made him eligible to undergo T-cell replete allogeneic stem transplantation from his sibling. •This report is the first to highlight the role of alemtuzumab, an anti-CD52 monoclonal antibody, in clonal disorders originating from transdifferentiation. •The alemtuzumab-based regimen should be reserved only for carefully selected allogeneic transplant patients.

Author List

Abid MB, Wadera K, Bird JM, Pawade J, Marks DI

Author

Muhammad Bilal Abid MD Assistant Professor in the Medicine department at Medical College of Wisconsin